Author: Linder, Kathleen A; McDonald, Philip J; Kauffman, Carol A; Revankar, Sanjay G; Chandrasekar, Pranatharthi H; Miceli, Marisa H
Title: Infectious Complications After Umbilical Cord Blood Transplantation for Hematological Malignancy Document date: 2019_2_22
ID: qu20hqch_36
Snippet: In the current study, we describe the burden of infectious complications in adult patients after UCBT. Prior studies have demonstrated the high infection risk in children after this procedure, but there are contradictory studies regarding the risk of infection in adult patients after UCBT [5, 6, 18] . Viral infections have been associated with excess morbidity and mortality after UCBT [6, 13, 19] . Cytomegalovirus reactivation has been of particu.....
Document: In the current study, we describe the burden of infectious complications in adult patients after UCBT. Prior studies have demonstrated the high infection risk in children after this procedure, but there are contradictory studies regarding the risk of infection in adult patients after UCBT [5, 6, 18] . Viral infections have been associated with excess morbidity and mortality after UCBT [6, 13, 19] . Cytomegalovirus reactivation has been of particular concern. Positive CMV serostatus of the recipient and use of ATG or monoclonal T-cell antibodies during conditioning are known risk factors for CMV reactivation and increased mortality after UCBT [6, [20] [21] [22] . Previous studies of infection after UCBT found rates of CMV reactivation from 21% to 64% and noted that these rates were higher than those noted after allogeneic HCT [13, 18, [22] [23] [24] . The use of ATG at conditioning in UCBT recipients has previously been associated with increased risk of CMV reactivation [13] . In our study, CMV reactivation was not associated with ATG use, but only 3 patients had received this agent. Cytomegalovirus infection did not contribute to the death of any patient in our cohort.
Search related documents:
Co phrase search for related documents- CMV serostatus and cytomegalovirus infection: 1
- CMV serostatus and Cytomegalovirus reactivation: 1
- CMV serostatus and risk factor: 1
- cohort patient and current study: 1, 2, 3, 4, 5
- cohort patient and Cytomegalovirus reactivation: 1
- cohort patient and high infection: 1, 2, 3, 4, 5, 6, 7, 8, 9
- cohort patient and increase mortality: 1, 2, 3
- cohort patient and increase risk: 1, 2, 3, 4, 5, 6, 7, 8
- cohort patient and previous study: 1
- cohort patient and prior study: 1
- cohort patient and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- cohort patient and viral infection: 1, 2, 3, 4, 5
- cohort patient death and current study: 1
- previous study and prior study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- previous study and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- previous study and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- prior study and risk factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- prior study and viral infection: 1, 2, 3, 4, 5, 6, 7
- risk factor and viral infection: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74
Co phrase search for related documents, hyperlinks ordered by date